Barr Pharmaceuticals Shuffles Managers
r> Christine Mundkur, Esq. has been named Chief Executive Officer of Barr Laboratories, Inc., the Company's generic pharmaceutical business.
Fred Wilkinson has been named Chief Executive Officer of Duramed Pharmaceuticals, the Company's proprietary products business.
Mike Bogda has been named President and Chief Operating Officer, Barr Laboratories, Inc., reporting to Mundkur; and, Timothy Sawyer has been named Executive Vice President, Global Generic Sales and Marketing, Barr Laboratories, Inc. reporting to Mundkur.
Christine Mundkur will have responsibility for Barr's global generics business.
Ms. Mundkur joined Barr in 1993 as an associate counsel and was named regulatory counsel and director of regulatory affairs in 1997.
In 1998, Ms. Mundkur was promoted to Vice President, Quality and Regulatory Counsel, and in 2001, she was promoted to Senior Vice President of Quality and Regulatory Counsel.
Ms. Mundkur most recently served as Executive Vice President Global Quality, Safety and Regulatory Affairs.
During 2007, Ms. Mundkur lived and worked in the Company's European headquarters in Zagreb, Croatia.
Fred Wilkinson has been named to the newly created position of Chief Executive Officer of Duramed Pharmaceuticals, Barr's proprietary products business.
Mr. Wilkinson will also continue directing Barr's growing global biologics development program.
Mr. Wilkinson joined the company in 2006.
Prior to joining Duramed Pharmaceuticals, Mr. Wilkinson served as Chief Executive Officer, President and a member of the Board of Directors of Columbia Laboratories from 2001.
From 1996 to 2001, Nr. Wilkinson served as Watson Pharmaceuticals' Chief Operating Officer and Senior Vice President, and he spent sixteen years at Sandoz Pharmaceutical Corporation in numerous senior managerial positions.
Mike Bogda has been named President and Chief Operating Officer of Barr Laboratories, Inc.
Mr. Bogda joined Barr in 2000 as Vice President of Validation and Technical Services and has held positions of increasing responsibility.
He was promoted to Senior Vice President, Manufacturing and Engineering in 2001, and most recently served as Executive Vice President, Global Product Supply.
Mr. Bogda joined Barr from Copley Pharmaceuticals, Inc. where his responsibilities included managing the consolidation and integration of Copley's manufacturing plants after the company's acquisition by Teva Pharmaceuticals USA. ■